Hypera S.A.

OTCPK:HYPM.Y Stock Report

Market Cap: US$2.8b

Hypera Valuation

Is HYPM.Y undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of HYPM.Y when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: HYPM.Y ($4.35) is trading below our estimate of fair value ($12.1)

Significantly Below Future Cash Flow Value: HYPM.Y is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HYPM.Y?

Key metric: As HYPM.Y is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for HYPM.Y. This is calculated by dividing HYPM.Y's market cap by their current earnings.
What is HYPM.Y's PE Ratio?
PE Ratio18.9x
EarningsR$825.30m
Market CapR$15.02b

Price to Earnings Ratio vs Peers

How does HYPM.Y's PE Ratio compare to its peers?

The above table shows the PE ratio for HYPM.Y vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average26.9x
PBH Prestige Consumer Healthcare
16x5.09%US$3.1b
BHC Bausch Health Companies
6.9x8.53%US$2.6b
OGN Organon
4.9x19.13%US$2.3b
LGND Ligand Pharmaceuticals
79.6x22.53%US$3.8b
HYPM.Y Hypera
18.2x26.58%US$14.8b

Price-To-Earnings vs Peers: HYPM.Y is good value based on its Price-To-Earnings Ratio (18.2x) compared to the peer average (26.7x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does HYPM.Y's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

9 CompaniesPrice / EarningsEstimated GrowthMarket Cap
NDOI Endo
0.3xn/aUS$1.76b
CRMD CorMedix
3.3x4.39%US$534.19m
ORMP Oramed Pharmaceuticals
3.2xn/aUS$146.47m
BTMD biote
2.5x-52.79%US$105.94m
HYPM.Y 18.9xIndustry Avg. 20.5xNo. of Companies9PE01632486480+
9 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: HYPM.Y is good value based on its Price-To-Earnings Ratio (18.2x) compared to the US Pharmaceuticals industry average (20.7x).

Price to Earnings Ratio vs Fair Ratio

What is HYPM.Y's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HYPM.Y PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio18.9x
Fair PE Ratio24.2x

Price-To-Earnings vs Fair Ratio: HYPM.Y is good value based on its Price-To-Earnings Ratio (18.2x) compared to the estimated Fair Price-To-Earnings Ratio (24.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

US$5.62
Fair Value
18.4% undervalued intrinsic discount
13
Number of Analysts

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/21 22:36
End of Day Share Price 2026/01/21 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hypera S.A. is covered by 23 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andréa AznarBB Banco de Investimento S.A.
Robert Ford AguilarBofA Global Research
Marcio OsakoBradesco S.A. Corretora de Títulos e Valores Mobiliários